Apomorphine News and Research

RSS

Study finds two substances capable of inhibiting proliferation of glioblastoma cells

Glioblastoma is a malignant tumor of the central nervous system (brain or spinal cord) and one of the deadliest types of cancer.

7 Mar 2023

Journal Of Parkinson's Disease announces recipients of first Parkinson Prize

The Journal of Parkinson's Disease and its publisher IOS Press are proud to announce the two articles that have won the first Parkinson Prize, recognizing these outstanding contributions to the advancement to Parkinson's disease research.

23 Jul 2020

Apomorphine infusion found to be effective treatment for Parkinson’s patients with motor fluctuations

Apomorphine subcutaneous infusion is an effective treatment for Parkinson patients whose motor fluctuations are poorly controlled by conventional therapies.

28 Jun 2017

Study shows evidence that old drug may provide relief for advanced Parkinson's disease patients

New research provides evidence that an old drug may provide relief for people with advanced Parkinson's, according to a study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.

20 Apr 2017

New infusion therapy may help avoid debilitating symptoms in Parkinson's disease patients

Constant infusion of a drug now used intermittently to "rescue" patients with Parkinson's from bouts of immobility may also help avoid these debilitating symptoms and smooth out their movement throughout the day, physician-scientists say.

14 Feb 2017

New study stresses importance of studying freezing episodes in Parkinson's patients

A recent study, led by Ryan P. Duncan of Washington University at St. Louis, suggested patients with Parkinson's disease who suffer from freezing episodes are more likely to have impaired balance than those who do not. This is an important discovery as Parkinson's disease typically develops in elderly patients, who cannot afford to be unstable, lose balance and potentially fall, which could result in major injuries.

12 Nov 2013

NIH issues SBIR grant to Titan Pharmaceutical for PD treatment development

Titan Pharmaceuticals, Inc. today announced that the National Institutes of Health has awarded the company a grant under the Small Business Innovation Research program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease. The first year award in the amount of $300,000 will be available to Titan starting August 1, 2010, and an additional $195,000 for the second year starting August 1, 2011 has been recommended subject to availability of funds and satisfactory progress of the project. The grant will be administered by the National Institute of Neurological Disorders and Stroke.

27 Jul 2010

Parkinson's patients find facial and vocal expression difficult to read; deep brain stimulation seems to make it worse

Scientists are beginning to find out why people with Parkinson's disease often feel socially awkward. Parkinson's patients find it harder to recognize expressions of emotion in other people's faces and voices, report two studies published by the American Psychological Association.

4 Mar 2010

Schizophrenia may arise from a single genetic defect

Researchers have long puzzled over the apparently multiple causes of complex developmental disorders such as schizophrenia. Individuals seem to be predisposed to the disease by a tragic, mysterious combination of genetics, prenatal trauma, viral infection, and early experience.

16 Feb 2005

Britannia Pharmaceuticals’ partner receives FDA approval for Parkinson’s disease treatment

Britannia Pharmaceuticals Limited announced today that U.S.-based Bertek Pharmaceuticals Inc., the branded subsidiary of Mylan Laboratories Inc has received approval from the Food and Drug Administration for APOKYN (apomorphine hydrochloride injection).

13 May 2004

Mylan announces FDA approval of Parkinson’s disease drug

The FDA approval clears the way for Bertek to market APOKYN and provides a new therapy for “off” episodes, one of the most debilitating aspects suffered by patients with Parkinson’s disease.

5 May 2004

FDA approves new breakthrough Parkinson's drug

FDA has approved Apokyn (apomorphine) as an injectable drug for treating Parkinson's patients during episodes of "hypomobility," so-called "off periods" in which the patient becomes immobile or unable to perform activities of daily living.

21 Apr 2004